ZUG, Switzerland--(BUSINESS WIRE)--Covis Pharma B.V. (“Covis Pharma”), a global specialty pharmaceutical company, is pleased to announce an agreement with Walgreens, one of the largest drugstore ...

U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) filing to study the use of Alvesco in COVID-19 Study will evaluate the Safety and Efficacy of Alvesco ...

The decision by Sepracor to in-license the US marketing rights to inhaled corticosteroid Alvesco caps a four-year commercial and regulatory odyssey for the asthma drug. Alvesco was approved earlier ...

At all Walgreens locations, Alvesco will be available at no cost or reduced cost to eligible patients “Asthma is one of the country’s most common diseases, impacting 25 million individuals across the ...

Study will evaluate the Safety and Efficacy of Alvesco in the Treatment of Non-hospitalized COVID-19 Patients Aged 12 and Above LUXEMBOURG and ZUG, Switzerland, May 19, 2020 /CNW/ -- Covis Pharma B.V.